MSD

News

MSD records one hit, one miss with TL1A drug tulisokibart

MSD's tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but has failed a study in rare lung disorder SSc-ILD.

News

Lawmakers seek answers from RFK on Gardasil shot settlement

Four Democratic senators are investigating whether the family of HHS Secretary RFK Jr is profiting from what they assert are "bogus" vaccine lawsuits.

News

Gilead, MSD share data on once-weekly oral HIV treatment

Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.

News

MSD gets first FDA okay for oral PCSK9 cholesterol drug

MSD has won the race to bring an oral PCSK9 inhibitor through to regulatory approval for LDL cholesterol-lowering in the US.

News

AZ pays $200m upfront for Sino Bio COPD drug

AstraZeneca has licensed a drug candidate for COPD from China's Sino Bio, which could compete with MSD's Ohtuvayre, in a deal valued at up to $2.1bn.

News

With measles cases rising, UK launches vaccination drive

With measles cases rising, the UK has launched a campaign urging around a million families to book the new four-in-one MMRV vaccine.

MSD records one hit, one miss with TL1A drug tulisokibart

Lawmakers seek answers from RFK on Gardasil shot settlement

Gilead, MSD share data on once-weekly oral HIV treatment

MSD gets first FDA okay for oral PCSK9 cholesterol drug

AZ pays $200m upfront for Sino Bio COPD drug

With measles cases rising, UK launches vaccination drive

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

MSD

Editor's Picks